Whitfield Assists Kelun-Biotech on its HK$2.7 Billion H-Share Placing
Overview
Kelun-Biotech completed an H-share placement on July 10, 2026, following its July 8 announcement, according to the source.
Net proceeds
The transaction raised approximately HK$2.723 billion after fees and costs. Goldman Sachs, Citigroup and J.P. Morgan were identified as placing agents.
Funding plans
The company intended to support research, trials, regulatory filings, manufacturing and commercialization, alongside collaboration, pipeline expansion, working capital and general purposes.
Named advisers
Mengyu Lu, George Zheng and Yuchen Han are the capital markets advisers credited for the placement. The source concerns the agents' representation rather than a new initial listing.
